Elaheh Karimi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Elaheh Karimi has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Hoda Kavosi
Rheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
3 shared publications - Zahra Moradi
School of Medicine Tehran University of Medical Sciences Tehran Iran
2 shared publications - Zahra Tamartash
Rheumatology Research center, Tehran University of medical sciences, Tehran, Iran
2 shared publications - Aida Mohamadi
Rheumatology Research Center, Tehran University of Medical Sciences, Iran, Islamic Republic of
1 shared publication - Ali Jafarian
Liver Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication Ali Nasrollahizadeh
Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
Delivery Choice in Pregnancies Complicated by Cardiac Disease: A Systematic Review and Meta‐Analysis Based on Modified World Health Organization Staging
Introduction: Cardiovascular conditions represent a leading cause of indirect maternal morbidity, making delivery planning a critical component of care in affected pregnancies. To evaluate the delivery mode selection in pregnancies complicated by cardiac disease, stratified by disease severity according to the modified World Health Organization (mWHO) staging system. Methods: We conducted comprehensive searches in four major electronic databases (PubMed, Web of Science, Scopus, and Embase) for literature published through July 11, 2025. The electronic search was supplemented by manual screening of reference lists from included studies. We included peer‐reviewed English full‐text studies with ≥ 15 participants that reported delivery modes in pregnant women with cardiac disease, categorized by mWHO stages (I‐IV). Both observational and interventional study designs were eligible. Our primary outcome was the rate of cesarean delivery (CS), with assisted vaginal delivery (AVD) rates analyzed as a secondary outcome. Study quality was assessed using the Joanna Briggs Institute Critical Appraisal Checklists. We performed random‐effects meta‐analyses to pool delivery method prevalence estimates. Subgroup analyses stratified studies by country income level (World Bank gross national income per capita categories) to examine socioeconomic influences on delivery choice. Results: From 26 eligible cohort studies ( n = 89,333 pregnancies with cardiac disease), 24 met quality criteria for meta‐analysis. Pooled CS rates increased progressively with mWHO severity: Stage I (40.6% [95% CI: 28.8%–52.4%]), Stage II (43.4% [95% CI: 31.5%–55.4%]), Stage II/III (50.0% [95% CI: 36.5%–63.5%]), Stage III (56.0% [95% CI: 42.0%–70.0%]), and Stage IV (67.8% [95% CI: 50.4%–85.2%]). For combined risk categories, low‐risk (mWHO I‐II) pregnancies showed lower intervention rates (CS: 39.2% [95% CI: 32.8%–45.7%]; AVD: 13.9% [95% CI: 7.0%–20.8%]) compared to high‐risk (mWHO III‐IV) pregnancies (CS: 57.7% [95% CI: 49.1%–66.2%]; AVD: 16.6% [95% CI: 8.6%–24.7%]). Notably, higher‐income countries demonstrated significantly lower CS rates in both low‐ and high‐risk groups ( p < 0.05), suggesting socioeconomic influences on delivery decisions. Conclusion: This study documents concerning CS overuse in cardiac pregnancies with disease severities. Current guidelines recommend vaginal delivery as standard practice, reserving surgical intervention for specific obstetric or critical cardiac conditions. However, our findings suggest a substantial gap between clinical practice and current guideline recommendations in this regard, requiring extensive attention. PROSPERO Registration: The review protocol was registered on 11/10/2024 under reference number CRD42024608358.
Delivery Choice in Pregnancies Complicated by Cardiac Disease: A Systematic Review and Meta‐Analysis Based on Modified World Health Organization Staging
Introduction: Cardiovascular conditions represent a leading cause of indirect maternal morbidity, making delivery planning a critical component of care in affected pregnancies. To evaluate the delivery mode selection in pregnancies complicated by cardiac disease, stratified by disease severity according to the modified World Health Organization (mWHO) staging system. Methods: We conducted comprehensive searches in four major electronic databases (PubMed, Web of Science, Scopus, and Embase) for literature published through July 11, 2025. The electronic search was supplemented by manual screening of reference lists from included studies. We included peer‐reviewed English full‐text studies with ≥ 15 participants that reported delivery modes in pregnant women with cardiac disease, categorized by mWHO stages (I‐IV). Both observational and interventional study designs were eligible. Our primary outcome was the rate of cesarean delivery (CS), with assisted vaginal delivery (AVD) rates analyzed as a secondary outcome. Study quality was assessed using the Joanna Briggs Institute Critical Appraisal Checklists. We performed random‐effects meta‐analyses to pool delivery method prevalence estimates. Subgroup analyses stratified studies by country income level (World Bank gross national income per capita categories) to examine socioeconomic influences on delivery choice. Results: From 26 eligible cohort studies ( n = 89,333 pregnancies with cardiac disease), 24 met quality criteria for meta‐analysis. Pooled CS rates increased progressively with mWHO severity: Stage I (40.6% [95% CI: 28.8%–52.4%]), Stage II (43.4% [95% CI: 31.5%–55.4%]), Stage II/III (50.0% [95% CI: 36.5%–63.5%]), Stage III (56.0% [95% CI: 42.0%–70.0%]), and Stage IV (67.8% [95% CI: 50.4%–85.2%]). For combined risk categories, low‐risk (mWHO I‐II) pregnancies showed lower intervention rates (CS: 39.2% [95% CI: 32.8%–45.7%]; AVD: 13.9% [95% CI: 7.0%–20.8%]) compared to high‐risk (mWHO III‐IV) pregnancies (CS: 57.7% [95% CI: 49.1%–66.2%]; AVD: 16.6% [95% CI: 8.6%–24.7%]). Notably, higher‐income countries demonstrated significantly lower CS rates in both low‐ and high‐risk groups ( p < 0.05), suggesting socioeconomic influences on delivery decisions. Conclusion: This study documents concerning CS overuse in cardiac pregnancies with disease severities. Current guidelines recommend vaginal delivery as standard practice, reserving surgical intervention for specific obstetric or critical cardiac conditions. However, our findings suggest a substantial gap between clinical practice and current guideline recommendations in this regard, requiring extensive attention. PROSPERO Registration: The review protocol was registered on 11/10/2024 under reference number CRD42024608358.
- Open Access
- 18 March 2026
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 14 (3) , e70377
Cytomegalovirus Infection Mimics Manifestations of Underlying Diseases in Patients With Autoimmune Disorders: A Case Report and Literature Review
Background: Patients with autoimmune disorders are highly susceptible to infections including cytomegalovirus (CMV) leading to serious complications ranging from asymptomatic to severe systemic diseases. Case Presentation: The first case was a 44‐year‐old woman with systemic lupus erythematosus (SLE) referred to the Rheumatology ward due to a necrotizing ulcer on the hand's finger and multiple ulcerative lesions on her lips and tongue. She had pancytopenia and tested positive for both herpes simplex virus (HSV) and CMV polymerase chain reaction (CMV‐PCR). She was treated with ganciclovir for 14 days and subsequently recovered. The second case was a 55‐year‐old man, a known sarcoidosis case, admitted to the hospital due to lower extremities weakness and intraoral ulcers. The lab findings revealed leukopenia and elevated levels of ESR and CRP. Viral markers were all negative except for the CMV‐PCR test. Electromyography and nerve conduction velocity (EMG‐NCV) showed subacute axonal motor polyneuropathy in the lower limbs. Due to the high titers of CMV (500,000 copies/mL), he was treated with ganciclovir for 2 weeks and the symptoms improved dramatically. Conclusion: CMV infection in patients with inflammatory rheumatic diseases may lead to rare manifestations that can be misdiagnosed as a flare of the underlying disease.
- 18 March 2026
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 14 (3) , e70377
Open AccessCytomegalovirus Infection Mimics Manifestations of Underlying Diseases in Patients With Autoimmune Disorders: A Case Report and Literature Review
Background: Patients with autoimmune disorders are highly susceptible to infections including cytomegalovirus (CMV) leading to serious complications ranging from asymptomatic to severe systemic diseases. Case Presentation: The first case was a 44‐year‐old woman with systemic lupus erythematosus (SLE) referred to the Rheumatology ward due to a necrotizing ulcer on the hand's finger and multiple ulcerative lesions on her lips and tongue. She had pancytopenia and tested positive for both herpes simplex virus (HSV) and CMV polymerase chain reaction (CMV‐PCR). She was treated with ganciclovir for 14 days and subsequently recovered. The second case was a 55‐year‐old man, a known sarcoidosis case, admitted to the hospital due to lower extremities weakness and intraoral ulcers. The lab findings revealed leukopenia and elevated levels of ESR and CRP. Viral markers were all negative except for the CMV‐PCR test. Electromyography and nerve conduction velocity (EMG‐NCV) showed subacute axonal motor polyneuropathy in the lower limbs. Due to the high titers of CMV (500,000 copies/mL), he was treated with ganciclovir for 2 weeks and the symptoms improved dramatically. Conclusion: CMV infection in patients with inflammatory rheumatic diseases may lead to rare manifestations that can be misdiagnosed as a flare of the underlying disease.
- Open Access
- 25 February 2026
- Published by PAGEPress Publications in Reumatismo
- Vol. 78 (1)
Computed tomography of interstitial lung disease in systemic sclerosis: dataset and deep learning model for pulmonary lesion segmentation
Objective. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a major cause of morbidity and mortality in systemic sclerosis patients. High-resolution computed tomography (HRCT) plays a crucial role in SSc-ILD diagnosis and management. In this study, we aimed to develop and evaluate a deep learning-based automated segmentation model for quantifying SSc-ILD lesions in HRCT images and assess its clinical relevance. Methods. We developed a convolutional neural network model to segment normal lung, established fibrosis (EF), and ground-glass opacity (GGO) in HRCT scans from 40 SSc-ILD patients. The model was trained and evaluated using 8-fold cross-validation. Segmentation performance was assessed using the Dice similarity coefficient (DSC). Correlations between predicted lesion volumes and pulmonary function test (PFT) metrics were analyzed using Spearman’s ρ. Results. Our model achieved a total lesion (EF+GGO) DSC of 78%. Class-wise segmentation performance was lower for EF (DSC: 70%) compared to GGO (DSC: 73%). Predicted lesion volumes showed significant negative correlations with forced expiratory volume in one second (FEV1) (ρ=-0.64, p<0.001) and FEV1/forced vital capacity (ρ=-0.73, p<0.001). We also created the SICCS dataset, a public dataset of SSc-ILD HRCT images with expert-annotated segmentation labels. Conclusions. Deep learning-based automated segmentation can help quantify SSc-ILD lesions in HRCT images and provide clinically relevant information. The model’s performance is comparable to previous studies, and the predicted lesion volumes correlate significantly with PFT metrics. This approach shows promise for aiding in SSc-ILD diagnosis, monitoring, and clinical decision-making, although further validation with larger datasets is needed.
- 25 February 2026
- Published by PAGEPress Publications in Reumatismo
- Vol. 78 (1)
Open AccessComputed tomography of interstitial lung disease in systemic sclerosis: dataset and deep learning model for pulmonary lesion segmentation
Objective. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a major cause of morbidity and mortality in systemic sclerosis patients. High-resolution computed tomography (HRCT) plays a crucial role in SSc-ILD diagnosis and management. In this study, we aimed to develop and evaluate a deep learning-based automated segmentation model for quantifying SSc-ILD lesions in HRCT images and assess its clinical relevance. Methods. We developed a convolutional neural network model to segment normal lung, established fibrosis (EF), and ground-glass opacity (GGO) in HRCT scans from 40 SSc-ILD patients. The model was trained and evaluated using 8-fold cross-validation. Segmentation performance was assessed using the Dice similarity coefficient (DSC). Correlations between predicted lesion volumes and pulmonary function test (PFT) metrics were analyzed using Spearman’s ρ. Results. Our model achieved a total lesion (EF+GGO) DSC of 78%. Class-wise segmentation performance was lower for EF (DSC: 70%) compared to GGO (DSC: 73%). Predicted lesion volumes showed significant negative correlations with forced expiratory volume in one second (FEV1) (ρ=-0.64, p<0.001) and FEV1/forced vital capacity (ρ=-0.73, p<0.001). We also created the SICCS dataset, a public dataset of SSc-ILD HRCT images with expert-annotated segmentation labels. Conclusions. Deep learning-based automated segmentation can help quantify SSc-ILD lesions in HRCT images and provide clinically relevant information. The model’s performance is comparable to previous studies, and the predicted lesion volumes correlate significantly with PFT metrics. This approach shows promise for aiding in SSc-ILD diagnosis, monitoring, and clinical decision-making, although further validation with larger datasets is needed.
- Open Access
- 30 April 2025
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 25 (1) , 1-19
Abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials
Dual antiplatelet therapy (DAPT), combining aspirin and a P2Y12 receptor inhibitor, is a standard post-percutaneous coronary intervention (PCI) treatment to reduce thrombosis and ischemic events. However, the optimal DAPT duration remains unclear, with concerns about bleeding risks associated with long-term potent P2Y12 inhibitors. This systematic review and meta-analysis investigates the safety and efficacy of shortened DAPT regimens. A comprehensive search of PubMed, Scopus, and EMBASE identified randomized controlled trials (RCTs) comparing conventional DAPT (≥ 12 months) and abbreviated DAPT (≤ 3 months) post-PCI. Primary outcomes were 1-year all-cause mortality and bleeding, assessed using the Bleeding Academic Research Consortium (BARC) classification. Secondary outcomes included cardiovascular mortality, non-fatal myocardial infarction (MI), stroke, and major adverse cardiovascular events (MACE). Risk of bias was assessed with the Cochrane tool, and meta-analyses used random-effects models. Forty studies involving 54,233 participants were included. Abbreviated DAPT significantly reduced all-cause mortality (RR: 0.90, 95%CI: 0.82–0.98) and bleeding (BARC 3 or 5: RR: 0.77, 95%CI: 0.60–0.97). No significant differences were observed in cardiovascular mortality, stroke, non-fatal MI, revascularization, or in-stent thrombosis. Subgroup analyses showed lower mortality with 1-month DAPT and reduced bleeding in patients with high bleeding risk, acute coronary syndrome (ACS), and complex PCI. Abbreviated DAPT post-PCI is associated with lower all-cause mortality and bleeding without compromising ischemic protection, supporting its use in specific patient populations. Individualized DAPT durations should be considered to balance bleeding and ischemic risks.
- 30 April 2025
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 25 (1) , 1-19
Open AccessAbbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials
Dual antiplatelet therapy (DAPT), combining aspirin and a P2Y12 receptor inhibitor, is a standard post-percutaneous coronary intervention (PCI) treatment to reduce thrombosis and ischemic events. However, the optimal DAPT duration remains unclear, with concerns about bleeding risks associated with long-term potent P2Y12 inhibitors. This systematic review and meta-analysis investigates the safety and efficacy of shortened DAPT regimens. A comprehensive search of PubMed, Scopus, and EMBASE identified randomized controlled trials (RCTs) comparing conventional DAPT (≥ 12 months) and abbreviated DAPT (≤ 3 months) post-PCI. Primary outcomes were 1-year all-cause mortality and bleeding, assessed using the Bleeding Academic Research Consortium (BARC) classification. Secondary outcomes included cardiovascular mortality, non-fatal myocardial infarction (MI), stroke, and major adverse cardiovascular events (MACE). Risk of bias was assessed with the Cochrane tool, and meta-analyses used random-effects models. Forty studies involving 54,233 participants were included. Abbreviated DAPT significantly reduced all-cause mortality (RR: 0.90, 95%CI: 0.82–0.98) and bleeding (BARC 3 or 5: RR: 0.77, 95%CI: 0.60–0.97). No significant differences were observed in cardiovascular mortality, stroke, non-fatal MI, revascularization, or in-stent thrombosis. Subgroup analyses showed lower mortality with 1-month DAPT and reduced bleeding in patients with high bleeding risk, acute coronary syndrome (ACS), and complex PCI. Abbreviated DAPT post-PCI is associated with lower all-cause mortality and bleeding without compromising ischemic protection, supporting its use in specific patient populations. Individualized DAPT durations should be considered to balance bleeding and ischemic risks.
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Medicine
- Vol. 2025 (1) , 8858671
Arrhythmia as a Possible Complication of Mycophenolate Mofetil in Systemic Sclerosis: A Case Report
A 55‐year‐old male patient with diffuse cutaneous systemic sclerosis (dcSSC) since 2018 presented with a history of arrhythmia. He had been stable for 5 years with pantoprazole, diltiazem, and mycophenolate mofetil (MMF); vitamin E; and vitamin D until he developed arrhythmia. Different evaluations revealed left bundle branch block, wall motion abnormality, mildly reduced systolic function, diffused interstitial fibrosis, and lesions in the left circumflex artery (LCX) and left anterior descending artery (LAD) and stenosis in LCX, without significant improvement following percutaneous coronary intervention for LCX stenosis. Holter monitoring demonstrated persistent ventricular premature beats and couplets. Arrhythmia was not responsive to bisoprolol therapy, and it was not feasible to perform cardiac ablation. Suspecting MMF–induced arrhythmia, MMF was discontinued, which led to a reduction in arrhythmia and symptom improvement after 9 months. This case report emphasized a possible heart‐related complication of MMF, which healthcare providers should consider when prescribing medication to patients.
- 1 January 2025
- Published by Wiley in Case Reports in Medicine
- Vol. 2025 (1) , 8858671
Open AccessArrhythmia as a Possible Complication of Mycophenolate Mofetil in Systemic Sclerosis: A Case Report
A 55‐year‐old male patient with diffuse cutaneous systemic sclerosis (dcSSC) since 2018 presented with a history of arrhythmia. He had been stable for 5 years with pantoprazole, diltiazem, and mycophenolate mofetil (MMF); vitamin E; and vitamin D until he developed arrhythmia. Different evaluations revealed left bundle branch block, wall motion abnormality, mildly reduced systolic function, diffused interstitial fibrosis, and lesions in the left circumflex artery (LCX) and left anterior descending artery (LAD) and stenosis in LCX, without significant improvement following percutaneous coronary intervention for LCX stenosis. Holter monitoring demonstrated persistent ventricular premature beats and couplets. Arrhythmia was not responsive to bisoprolol therapy, and it was not feasible to perform cardiac ablation. Suspecting MMF–induced arrhythmia, MMF was discontinued, which led to a reduction in arrhythmia and symptom improvement after 9 months. This case report emphasized a possible heart‐related complication of MMF, which healthcare providers should consider when prescribing medication to patients.
- 1 December 2021
- Published by Baskent University in Experimental and Clinical Transplantation
- Vol. 19 (12) , 1277-1285
Acute Kidney Injury After Liver Transplant: Incidence, Risk Factors, and Impact on Patient Outcomes
Acute kidney injury is a frequent complication of liver transplant. Here, we assessed the rate and contributing factors of acute kidney injury and need for renal replacement therapy in patients undergoing liver transplant at a transplant center in Tehran, Iran. We identified all patients who underwent liver transplant at the Imam Khomeini Hospital Complex from March 2018 to March 2019 and who were followed for 3 months after transplant. Acute kidney injury was defined based on the Acute Kidney Injury Network criteria. We collected demographic and pretransplant, intraoperative, and posttransplant data. Univariable and multivariable models were applied to explore independent risk factors for acute kidney injury incidence and need for renal replacement therapy. Our study included 173 deceased donor liver transplant recipients. Rates of incidence of acute kidney injury and need for renal replacement therapy were 68.2% and 14.5%, respectively. The 3-month mortality rate among those with severe and mild or moderate acute kidney injury was 44.0% (14/25) and 9.7% (9/ 93), respectively (P < .001). Multivariable analyses indicated that serum albumin (relative risk of 0.55; 95% confidence interval, 0.34-0.87; P = .021), baseline serum creatinine (relative risk of 2.11; 95% confidence interval, 1.56-2.90; P = .037), and intraoperative mean arterial pressure (relative risk of 0.76; 95% confidence interval, 0.63-0.82; P = .008) were independent factors for predicting posttransplant acute kidney injury. Independent risk factors for requiring renal replacement therapy were pretransplant serum creatinine (relative risk of 1.99; 95% confidence interval, 1.89-4.47; P = .044) and intraoperative vasopressor infusion (relative risk of 1.41; 95% confidence interval, 1.38-2.00; P = .021). We found a high incidence of acute kidney injury among liver transplant recipients in our center. There was a significant association between severity of acute kidney injury and 3-month and in-hospital mortality.
- 1 December 2021
- Published by Baskent University in Experimental and Clinical Transplantation
- Vol. 19 (12) , 1277-1285
Acute Kidney Injury After Liver Transplant: Incidence, Risk Factors, and Impact on Patient Outcomes
Acute kidney injury is a frequent complication of liver transplant. Here, we assessed the rate and contributing factors of acute kidney injury and need for renal replacement therapy in patients undergoing liver transplant at a transplant center in Tehran, Iran. We identified all patients who underwent liver transplant at the Imam Khomeini Hospital Complex from March 2018 to March 2019 and who were followed for 3 months after transplant. Acute kidney injury was defined based on the Acute Kidney Injury Network criteria. We collected demographic and pretransplant, intraoperative, and posttransplant data. Univariable and multivariable models were applied to explore independent risk factors for acute kidney injury incidence and need for renal replacement therapy. Our study included 173 deceased donor liver transplant recipients. Rates of incidence of acute kidney injury and need for renal replacement therapy were 68.2% and 14.5%, respectively. The 3-month mortality rate among those with severe and mild or moderate acute kidney injury was 44.0% (14/25) and 9.7% (9/ 93), respectively (P < .001). Multivariable analyses indicated that serum albumin (relative risk of 0.55; 95% confidence interval, 0.34-0.87; P = .021), baseline serum creatinine (relative risk of 2.11; 95% confidence interval, 1.56-2.90; P = .037), and intraoperative mean arterial pressure (relative risk of 0.76; 95% confidence interval, 0.63-0.82; P = .008) were independent factors for predicting posttransplant acute kidney injury. Independent risk factors for requiring renal replacement therapy were pretransplant serum creatinine (relative risk of 1.99; 95% confidence interval, 1.89-4.47; P = .044) and intraoperative vasopressor infusion (relative risk of 1.41; 95% confidence interval, 1.38-2.00; P = .021). We found a high incidence of acute kidney injury among liver transplant recipients in our center. There was a significant association between severity of acute kidney injury and 3-month and in-hospital mortality.